Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737068 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6141707 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL7520137 | 0.90 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12987975 | 0.89 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12987977 | 0.89 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL24359130 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19894397 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2580965 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL14389708 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL20732056 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 708 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601656-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2025-08-20 | — | — | EP | claimed |
| US-20240191231-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2024-06-13 | — | — | US | claimed |
| WO-2024077351-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2024-04-18 | — | — | WO | claimed |
| WO-2023154964-A1 | METHODS AND COMPOSITIONS FOR TARGETING EFEMP1 | ALLOY THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2022-04-14 | — | — | US | claimed |
| US-20220090071-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2022-03-24 | — | — | US | claimed |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2021-10-05 | — | — | US | claimed |
| US-11053503-B2 | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | KCL THERAPEUTICS, INC | 2021-07-06 | — | — | US | claimed |
| US-20190292540-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2019-09-26 | — | — | US | claimed |
| US-10266822-B2 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2019-04-23 | — | — | US | claimed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| JP-2002512794-A | — | — | 2002-05-08 | — | — | JP | claimed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | claimed |
| JP-2001525667-A | — | — | 2001-12-11 | — | — | JP | claimed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-1073732-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | claimed |
| US-6127535-A | FOR THE INCORPORATION OF MODIFIED (NON-STANDARD) AND UNMODIFIED NUCLEOTIDES INTO NUCLEIC ACIDS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| EP-0980424-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1999055857-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1998050530-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | SNRPE, AGO2, NSUN2 | SLC28A1 670/4885SLC28A2 743/4885SLC29A1 268/4885 |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | SNRPE, AGO2, NSUN2 | SLC28A1 670/4885SLC28A2 743/4885SLC29A1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.